p73 antibody | knockout validation

p73 antibody | knockout validation | Novus NBP2-24737

This is a knockout-validated antibody summary, based on the publication "CBFB cooperates with p53 to maintain TAp73 expression and suppress breast cancer", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Figure 1. IB shows the expression of TAp73, p53, CBFB, RUNX1, and β-actin in WT and p73_KO MCF10A cells. From [1].

Antibody information

Mouse monoclonal IgG1 Kappa

Company: Novus

Antibody: p73

Catalog number: NBP2-24737

Summary: Mouse monoclonal antibody against full-length human p73. It reacts with an epitope that is located on the N-terminal region of human p73. Reacts with human, mouse and rat. Suitable for western blot, immunocytochemistry/immunofluorescence, immunohistochemistry (paraffin and frozen), immunoprecipitation, flow cytometry and chromatin immunoprecipitation.

Validation Method

Western blot

Sample

WT and p73 KO MCF10A cells.

Blocking agent

5% non-fat milk in PBS-Tween 20.

Primary incubation

1:1,000 dilution overnight at 4°C.

Detection

ChemiDoc MP Imaging System (Bio-Rad).

Clone note

The same clone (5B429) is sold as Novus Biologicals NBP2-24737, NBP2-33259; OriGene TA337049; Santa Cruz Biotechnology sc-56191; LifeSpan Biosciences LS-B2086, LS-C368321; Abnova MAB12973; Rockland Immunochemicals 200-301-I00; Active Motif 40972; Invitrogen MA1-23147, MA5-16167.

References

Malik N, Yan H, Yang H, Ayaz G, DuBois W, Tseng Y, et al. CBFB cooperates with p53 to maintain TAp73 expression and suppress breast cancer. PLoS Genet. 2021;17:e1009553 pubmed publisher

contribute

If you are aware of any publication with knockout studies validating a monoclonal or recombinant antibody, either purchased from a supplier or developed by the author(s), please notify us through feedback.